atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference | Psychedelic Invest

NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements. Scott…

Stem cell gene therapy may offer a promising, curative treatment for sickle cell disease

New research published in the New England Journal of Medicine indicates that stem cell gene therapy may offer a promising, curative treatment for the painful,

August 31, 2023

MindBio Therapeutics Scientists Present Landmark Women’s Health Trials, Company to Release Phase 2A Depression Trial Secondary Data This Month | Psychedelic Invest

VANCOUVER – MindBio Therapeutics Corp. (CSE: MBIO) (Frankfurt: WF6), (the ‘Company’ or ‘MindBio’), a clinical stage biopharma company pioneering microdosing treatments for mental health conditions showcases Dr Rachael Sumner,

May 3, 2024

Summus Raises $19.5M to Expand Virtual Specialty Care Access

What You Should Know: – Summus, a New York City-based virtual health company focused on specialty care, has raised $19.5M in its latest funding round to

September 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.